Ultimovacs

Ultimovacs (OSE: ULTI)

Currency in NOK

Last close As at 03/02/2023

NOK120.60

▲ 0.80 (0.67%)

Market capitalisation

NOK4,121m

Overview
Price performance
Financials
Research
Thematics

Ultimovacs is developing novel immunotherapies against cancer. Lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase, which is expressed by c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

Healthcare

23.01.23

Ultimovacs — Phase II milestone as licensing potential nears

Healthcare

21.12.22

Ultimovacs — Slight adjustment but trial continues as planned

Healthcare

15.12.22

Ultimovacs — Prostate cancer trial patient enrolment complete

Healthcare

11.11.22

Ultimovacs — On track for upcoming UV1 catalysts

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

Carlos de Sousa

CEO
Gustav Gaudernack

CSO
Hans Vassgård Eid

CFO
Jens Bjørheim

CMO
Ton Berkien

CBO

Balance Sheet

Forecast net cash (NOKm)

346.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	8.5	54.6	18.2
Relative	9.7	57.0	21.4
52 week high/low	NOK127.0/NOK59.9

Financials

Ultimovacs has announced that patient enrolment has been completed (n=118) for the ongoing Phase II NIPU study investigating the company’s lead cancer vaccine candidate, UV1, in combination with immune checkpoint inhibitors (ICIs), ipilimumab and nivolumab, in the treatment of patients with pleural mesothelioma. We see the successful patient enrolment for the trial as a positive indicator of Ultimovacs being on track to deliver top-line readouts from the study, which are expected in H123, representing one of the company’s most important near-term catalysts. Additionally, positive data readouts from the trial could, in our view, support potential licensing opportunities for Ultimovacs. We maintain our valuation at NOK7.9bn or NOK231 per share.